Incyte

Incyte is a biopharmaceutical company focused on oncology and inflammatory diseases, best known for its blood-cancer drug Jakafi and a pipeline of therapies in dermatology and immunology. Its fortunes are tied closely to a relatively small number of key products, patent timelines and the success of its research programmes. Incyte does not pay a dividend, directing its cash flow into research and development and the expansion of its drug portfolio. There is no income here, and the low score reflects the absence of any payout combined with the concentrated, binary nature of drug-development risk. This is a growth and pipeline story rather than a shareholder-distribution one, appropriate for investors comfortable with biotech volatility.